Baxter International
Market Cap
US$38.7b
Last Updated
2021/07/31 05:32 UTC
Data Sources
Company Financials +
Executive Summary
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet and fair value.
Similar Companies
Share Price & News
How has Baxter International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BAX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BAX's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-4.7%
BAX
1.8%
US Medical Equipment
-0.5%
US Market
1 Year Return
-10.5%
BAX
31.7%
US Medical Equipment
35.9%
US Market
Return vs Industry: BAX underperformed the US Medical Equipment industry which returned 31.7% over the past year.
Return vs Market: BAX underperformed the US Market which returned 35.9% over the past year.
Shareholder returns
| BAX | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.7% | 1.8% | -0.5% |
| 30 Day | -5.1% | 5.2% | 0.3% |
| 90 Day | -9.7% | 6.5% | 3.1% |
| 1 Year | -9.3%-10.5% | 32.6%31.7% | 38.0%35.9% |
| 3 Year | 10.6%6.9% | 75.0%70.9% | 62.9%52.7% |
| 5 Year | 70.0%60.9% | 153.2%141.5% | 121.7%97.3% |
Long-Term Price Volatility Vs. Market
How volatile is Baxter International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Baxter International Inc. (NYSE:BAX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?2 weeks ago | Simply Wall St
Baxter International (NYSE:BAX) Shareholders Have Enjoyed A 73% Share Price Gain1 month ago | Simply Wall St
We Like These Underlying Return On Capital Trends At Baxter International (NYSE:BAX)Valuation
Is Baxter International undervalued compared to its fair value and its price relative to the market?
26.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BAX ($77.35) is trading below our estimate of fair value ($104.78)
Significantly Below Fair Value: BAX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BAX is good value based on its PE Ratio (35x) compared to the US Medical Equipment industry average (50.9x).
PE vs Market: BAX is poor value based on its PE Ratio (35x) compared to the US market (18x).
Price to Earnings Growth Ratio
PEG Ratio: BAX is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: BAX's PB Ratio (4.6x) is in line with the US Medical Equipment industry average.
Future Growth
How is Baxter International forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
12.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAX's forecast earnings growth (12.3% per year) is above the savings rate (2%).
Earnings vs Market: BAX's earnings (12.3% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: BAX's earnings are forecast to grow, but not significantly.
Revenue vs Market: BAX's revenue (4.8% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: BAX's revenue (4.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAX's Return on Equity is forecast to be high in 3 years time (22.9%)
Past Performance
How has Baxter International performed over the past 5 years?
-32.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BAX has a large one-off loss of $368.0M impacting its June 30 2021 financial results.
Growing Profit Margin: BAX's current net profit margins (9.2%) are higher than last year (8.1%).
Past Earnings Growth Analysis
Earnings Trend: BAX's earnings have declined by 32.6% per year over the past 5 years.
Accelerating Growth: BAX's earnings growth over the past year (21.2%) exceeds its 5-year average (-32.6% per year).
Earnings vs Industry: BAX earnings growth over the past year (21.2%) underperformed the Medical Equipment industry 33.2%.
Return on Equity
High ROE: BAX's Return on Equity (13.3%) is considered low.
Financial Health
How is Baxter International's financial position?
Financial Position Analysis
Short Term Liabilities: BAX's short term assets ($8.0B) exceed its short term liabilities ($3.3B).
Long Term Liabilities: BAX's short term assets ($8.0B) exceed its long term liabilities ($7.8B).
Debt to Equity History and Analysis
Debt Level: BAX's debt to equity ratio (70.9%) is considered high.
Reducing Debt: BAX's debt to equity ratio has increased from 37.2% to 70.9% over the past 5 years.
Debt Coverage: BAX's debt is well covered by operating cash flow (34.3%).
Interest Coverage: BAX's interest payments on its debt are well covered by EBIT (13.2x coverage).
Balance Sheet
Dividend
What is Baxter International current dividend yield, its reliability and sustainability?
1.45%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: BAX's dividend (1.45%) is higher than the bottom 25% of dividend payers in the US market (1.31%).
High Dividend: BAX's dividend (1.45%) is low compared to the top 25% of dividend payers in the US market (3.54%).
Stability and Growth of Payments
Stable Dividend: BAX's dividend payments have been volatile in the past 10 years.
Growing Dividend: BAX's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (45.9%), BAX's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BAX's dividends in 3 years are forecast to be well covered by earnings (32.3% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.2yrs
Average management tenure
CEO
Joe Almeida (59 yo)
5.5yrs
Tenure
US$15,865,396
Compensation
Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD15.87M) is above average for companies of similar size in the US market ($USD11.17M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: BAX's management team is considered experienced (4.2 years average tenure).
Board Members
Experienced Board: BAX's board of directors are considered experienced (5.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Baxter International Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Baxter International Inc.
- Ticker: BAX
- Exchange: NYSE
- Founded: 1931
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$38.668b
- Shares outstanding: 499.91m
- Website: https://www.baxter.com
Number of Employees
Location
- Baxter International Inc.
- One Baxter Parkway
- Deerfield
- Illinois
- 60015
- United States
Listings
Biography
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis the...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/07/31 05:32 |
| End of Day Share Price | 2021/07/30 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.